Table 6.
Specific CSF miRNA panel for studying neurodegenerative diseases
| Assay ID | miRNA | Selection criteria | Note |
|---|---|---|---|
| 000377 | hsa-let-7a | 1, 8 | ND in our array |
| 002619 | hsa-let-7b | 1, 8 | |
| 000379 | hsa-let-7c | 1, 8 | |
| 000382 | hsa-let-7f | 1, 2, 8 | ND in our array |
| 000439 | hsa-miR-103 | 1, 2, 3, 4 | |
| 002169 | hsa-miR-106a | 1, 2, 3, 4 | |
| 000443 | hsa-miR-107 | 1, 2, 3 | ND in our array |
| 000449 | hsa-miR-125b | 1, 2, 5 | |
| 002884 | hsa-miR-1274B | 1, 6 | |
| 002861 | hsa-miR-1298 | 1, 2 | |
| 000457 | hsa-miR-132 | 1, 2, 3 | |
| 000464 | hsa-miR-142-3p | 1, 2 | |
| 002248 | hsa-miR-142-5p | 1 | |
| 000468 | hsa-miR-146a | 1, 2 | |
| 001097 | hsa-miR-146b | 1, 2 | |
| 000473 | hsa-miR-150 | 1 | |
| 002623 | hsa-miR-155 | 1, 2 | |
| 000389 | hsa-miR-15a | 1, 2, 3, 4 | ND in our array |
| 000390 | hsa-miR-15b | 1, 2, 3, 4 | |
| 000391 | hsa-miR-16 | 1, 2, 3, 4 | |
| 002308 | hsa-miR-17 | 1, 3 | |
| 000480 | hsa-miR-181a | 1, 2 | ND in our array |
| 000482 | hsa-miR-181c | 1, 2 | ND in our array |
| 000494 | hsa-miR-195 | 1, 2, 3, 4 | |
| 000396 | hsa-miR-19b | 1, 2, 3 | |
| 000508 | hsa-miR-204 | 1, 3, 6 | |
| 000580 | hsa-miR-20a | 1, 3 | |
| 000397 | hsa-miR-21 | 1, 2, 7 | |
| 002295 | hsa-miR-223 | 1, 2, 7 | |
| 000402 | hsa-miR-24 | 1, 7 | |
| 000408 | hsa-miR-27a | 1, 2 | |
| 002112 | hsa-miR-29a | 1, 2, 4 | |
| 000413 | hsa-miR-29b | 1, 2, 4 | ND in our array |
| 000587 | hsa-miR-29c | 1, 2, 4 | |
| 000416 | hsa-miR-30a-3p | 1, 2, 6 | |
| 000417 | hsa-miR-30a-5p | 1, 2 | |
| 000602 | hsa-miR-30b | 1, 2, 6 | |
| 000419 | hsa-miR-30c | 1, 2, 6 | |
| 000420 | hsa-miR-30d | 1, 2 | |
| 000422 | hsa-miR-30e-3p | 1 | |
| 000426 | hsa-miR-34a | 1, 2 | |
| 002102 | hsa-miR-34b | 1, 2 | |
| 000428 | hsa-miR-34c | 1, 2 | |
| 001043 | hsa-miR-497 | 1, 2, 3, 4 | |
| 000583 | hsa-miR-9 | 1, 2, 5 | ND in our array |
| 001182 | mmu-miR-124a | 1, 2, 5 | ND in our array |
| 001141 | mmu-miR-451 | 1, 2 |
1 miRNA is detectable in CSF based on our profiling and existing literature, 2 miRNAwas previously associated with AD (in tissue or CSF or both) or other neurodegenerative pathology, 3 miRNA is predicted to target genes critical to AD pathways (e.g., MAPTau, BACE1), 4 miRNA belongs to miR-15/107 or miR-29 family which are hypothesized to be perturbed and/or involved in neurodegenerative diseases, 5 miRNA is particularly brain-enriched, 6 miRNA is a potential normalizer (CSF housekeeping miRNAs), 7 contamination controls, 8 ubiquitously expressed RNA species, ND not detected